AL-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from AL-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.
AL-LAD shares many common traits with its parent compound LSD; in humans it appears to be roughly equal (if slightly less) in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable - perhaps due to being catabolised more readily). In rats, however, AL-LAD was measured to be around twice the potency of LSD, and this may extend to AL-LAD.
There are currently anecdotal reports which describe the effects of this compound within our experience index.
The toxicity and long-term health effects of recreational AL-toxic dose is unknown. This is because AL-LAD is a research chemical with very little history of human usage.
The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute AL-LAD exposure. Although no formal studies have been conducted, it is likely that as with LSD itself, AL-LAD is able to be considered non-addictive,extremely low toxicity relative to dose. It is also likely that as with LSD, there are little to no negative physical, cognitive, psychiatric or other toxic consequences associated with acute AL-LAD exposure.
However, as with LSD and psychedelics in general, it is possible that AL-LAD can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.
It is strongly recommended that one uses harm reduction practices when using this substance.
Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, AL-not habit-forming and that the desire to use it can actually decrease with use.
Tolerance to the effects of AL-almost immediately after ingestion. After that,5-714 days to be back at baseline (in the absence of further consumption). AL-LAD presents cross-tolerance with Cross-all psychedelics, meaning that after the use of AL-LAD all psychedelics will have a reduced effect.
The LD50 of AL-LAD is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of AL-LAD.
AL-LAD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries, but people may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.
Austria: AL-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Denmark: As of August 25, 2015, AL-LAD is specifically named on the list of illegal substances.
Germany: AL-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: AL-LAD is a controlled substance in Japan effective February 28th, 2020.
Latvia: AL-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Sweden: Following its sale as a designer drug, AL-LAD was made illegal in Sweden on January 26, 2016.
Switzerland: 21 substances, including AL-LAD, were added to the list of illegal substances including on December 1, 2015. It is a controlled substance specifically named under Verzeichnis E.
Turkey: AL-LAD is illegal in Turkey as of February 2016.
United Kingdom: As of January 7, 2015, AL-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A controlled substance.
United States: AL-LAD is unscheduled but can be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelics
ETH-LAD
ALD-52
LSZ
LSD
AL-LAD (Wikipedia)
AL-LAD (TiHKAL / Isomer Design)
Discussion
The Big & Dandy AL-LAD Thread - Part 1 (Bluelight)
Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.
AL-LAD can be administered via oral. The route of administration can influence both the onset and intensity of difficulty urinating.